Phase II trial of oral aminopterin for adults and children with refractory acute leukemia - Wikidata - awgldk - TriplyDB

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

http://www.wikidata.org/entity/Q24606434

about

Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter.Establishment and assessment of a new human embryonic stem cell-based biomarker assay for developmental toxicity screening.LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy.Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL).

P2860

Q36174195-D7422F22-B878-4084-A988-3B016AED5D76 Q39079366-87E54240-56F3-4A01-8F7D-CBF43EED7DA5 Q42919472-62A11503-E35D-4EEB-BD0B-BE73D54586E9 Q47884623-82A4C9EA-4F92-415A-89F4-39B4AD824D2A

P2860

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

http://www.wikidata.org/entity/Q24606434

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@ast

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@en

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@nl

type

label

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@ast

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@en

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@nl

prefLabel

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@ast

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@en

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@nl

P1433

Q24606434-0DF7EC9F-7E92-41F7-AF9E-D451BA10D9E4

P1476

Q24606434-C066E3E8-96F6-46A4-BC91-1B2845F183C3

P2093

Q24606434-2EEC5758-7EC7-407E-887F-2430D41E786A

Q24606434-30C1ADFD-CF72-487D-B228-80DB612EB46E

Q24606434-5BF89A24-7661-4F29-A26A-048759E4CF4A

Q24606434-6DD8CB43-3B6F-4C91-B807-44405066C209

Q24606434-72D208AB-1C65-4B33-9DF1-934A1780FEAA

Q24606434-810DB737-78D6-45AF-A212-1AB575E99C6B

Q24606434-ADEC72D9-21B2-48A7-8FB0-C70068E8CC4E

Q24606434-F63B542C-31F2-4F1E-8208-D0420C3337C2

P2860

Q24606434-12A32FCC-A31B-4EEE-AAB6-FBF24B3CBF7F

Q24606434-1F7AF754-298F-416E-ACC9-06C363B947E6

Q24606434-25BA4A5F-3C64-41A2-9FCE-62DB68DCBEAA

Q24606434-2A52F68B-7355-45DA-BB7B-EC8A6E2886D4

Q24606434-3AB1DE9C-B58A-4ADB-879A-1E71C43E6CFF

Q24606434-3AE4AD27-A14A-4E32-9C28-2DAF291897F5

Q24606434-438B0256-04C1-4EAE-9D8B-F773CF7912D6

Q24606434-44531CC3-D0AB-4E07-809C-00A77F8921CD

Q24606434-4555DD7B-9383-4286-8983-E0182F0246D6

Q24606434-509705FB-87A4-4551-84C3-F6CADD554D70

P304

Q24606434-26AE8390-C4B9-42B2-931C-D571826FAE04

P31

Q24606434-B6C8094E-1B6B-414B-BDAB-DB7B2DEB7CCE

P356

Q24606434-893A11C5-30F8-48A0-8C83-C7F94FF95079

P407

Q24606434-ECA25439-6C25-422B-BDBA-B2759DCE1E6D

P433

Q24606434-F884B9E0-6233-4FAE-A3C4-155DD01AD38A

P478

Q24606434-F3FD26F8-49FB-41EB-9E6D-94C264DCA153

P50

Q24606434-90861700-16E6-47CE-B934-23B3A2AEDA96

P577

Q24606434-A304E0FA-034B-45BD-A747-B493BD1F9E4D

P698

Q24606434-6008C64A-37CB-43A2-8D22-6FACDFB106CB

P921

Q24606434-150B3A2A-2337-4EFC-8EC5-71E0F9D22176

Q24606434-2D5874F4-5F86-43F6-8F5C-E25BE007037D

P932

Q24606434-B1BDA30D-6CAE-4368-B6CB-6A43B7A461AD

P356

1078-0432.CCR-05-0355

P1433

Clinical Cancer Research

P1476

Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

@en

P2093

Angela K Smith

http://www.w3.org/2001/XMLSchema#string

Barton A Kamen

http://www.w3.org/2001/XMLSchema#string

Douglas S Hawkins

http://www.w3.org/2001/XMLSchema#string

John Holcenberg

http://www.w3.org/2001/XMLSchema#string

Kara Kelly

http://www.w3.org/2001/XMLSchema#string

Peter D Cole

http://www.w3.org/2001/XMLSchema#string

Richard A Drachtman

http://www.w3.org/2001/XMLSchema#string

Sarah Cate

http://www.w3.org/2001/XMLSchema#string

P2860

Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology

Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.

Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.

A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors.

A quantitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice.

Intrinsic and acquired resistance to methotrexate in acute leukemia.

Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.

P304

8089-8096

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-05-0355

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Richard A. Larson

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16299240

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2906753

http://www.w3.org/2001/XMLSchema#string